Results 121 to 130 of about 166,404,517 (251)

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley   +3 more
wiley   +1 more source

Chronic diseases in America [PDF]

open access: yes
6 IN 10 Adults in the US have a chronic disease4 IN 10 Adults in the US have two or moreTHE LEADING CAUSES OF DEATH AND DISABILITY and Leading Drivers of the Nation\u2019s $3.3 Trillion in Annual Health Care Costswww.cdc.gov/chronicdiseasePublication ...

core  

Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Parenteral artesunate is the preferred first‐line treatment for severe malaria. Pre‐referral rectal artesunate suppositories are recommended where parenteral treatment is inaccessible. In this study, we compared dihydroartemisinin exposure and model‐predicted early parasite clearance following rectal artesunate and intravenous artesunate in ...
Ayorinde Adehin   +6 more
wiley   +1 more source

The Four Domains of chronic disease prevention : working toward healthy people in healthy communities [PDF]

open access: yes
Modern efforts to prevent disease, help people lead healthier lives, and end health disparities must include a focus on chronic diseases.Chronic diseases\u2014heart disease and stroke, diabetes, cancer, chronic lung diseases, and others\u2014account for ...

core  

The impact of medication shortages on paediatric care: A retrospective impact analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Medication shortages are a growing global concern, with potentially greater consequences in paediatric patients because of the limited availability of safe, evidence‐based and appropriately formulated medication. This study aimed to evaluate the impact of medication shortages on paediatric patients by assessing the suitability and safety of ...
Maaike Johanna Rutten ‐ van Kranenburg   +6 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang   +5 more
wiley   +1 more source

GIS express for chronic disease ; v. 1, issue 1, May 15, 2018

open access: yes
We are excited to present the inaugural issue of the GIS Express for Chronic Disease. This newsletter is designed to keep you up-to-date about GIS-related information that is readily available from CDC\u2019s Division for Heart Disease and Stroke ...

core  

New therapeutic options for metabolic‐associated steatotic liver disease

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Anaemia of chronic disease. [PDF]

open access: yesClin Med (Lond), 2013
Cullis J.
europepmc   +1 more source

Home - About - Disclaimer - Privacy